NCT07341854

Dexamethasone Palmitate for Postoperative Pain

Effect of Intravenous Dexamethasone Palmitate on Postoperative Pain Prevention

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 446 (estimated)
• Sponsor: Beijing Tiantan Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Postoperative pain remains highly prevalent and inadequately managed in a significant proportion of surgical patients, often leading to delayed recovery, increased opioid consumption, and potential progression to chronic pain. While perioperative systemic dexamethasone is used for its anti-inflammatory and opioid-sparing effects, its efficacy is inconsistent, and concerns regarding systemic side effects persist. Dexamethasone palmitate, a novel lipophilic prodrug formulated as nanoparticle emulsion, leverages the enhanced permeability and retention effect to target inflammatory sites selectively, potentially offering superior anti-inflammatory and analgesic efficacy with reduced systemic exposure. This trial aims to evaluate whether preoperative intravenous dexamethasone palmitate is more effective than conventional dexamethasone in preventing moderate-to-severe postoperative pain.

Conditions

• Pain, Postoperative
• Dexamethasone Palmitate

Interventions

Type	Name	Description
DRUG	dexamethasone palmitate	Patients assigned to the dexamethasone palmitate group will receive an intravenous injection of 8 mg dexamethasone palmitate after induction of anaesthesia but prior to surgical incision.
DRUG	Dexamethasone	Patients in the dexamethasone group will receive an intravenous injection of 8 mg dexamethasone after induction of anaesthesia but prior to surgical incision.

Timeline

• Start date: 2026-06-01
• Primary completion: 2027-06-30
• Completion: 2027-12-30
• First posted: 2026-01-14
• Last updated: 2026-04-08

Locations

1 site across 1 country: China